A new study shows that nearly half of cancer patients experienced tumor disappearance or significant shrinkage after six months of treatment with ivermectin and mebendazole, according to epidemiologist Nicholas Holshire of the McCulla Foundation.
The research involved 200 patients with over 20 different cancer types, with 84.4 percent reporting clinical benefit from the antiparasitic drug combination. "84.4% of them did report to have benefited in their cancer," Holshire said. The most dramatic results showed complete disappearance or tumor shrinkage in 48 percent of cases.
The treatment demonstrated effectiveness across all cancer stages, including 37 percent of patients with metastatic stage 4 cancer. Holshire said the combination therapy works through multiple mechanisms including targeting cancer stem cells and inhibiting glucose metabolism in cancer cells.
Holshire claimed that ivermectin and related antiparasitics have been deliberately suppressed by pharmaceutical interests. "Ivermectin, antiparasitics, fenbendazol, mebendazole have been demonized by the biofarmaceutical complex," he said. He argued that economic factors played a role, claiming that chemotherapy costs patients over $100,000 per year while ivermectin treatment costs only a few thousand dollars.
According to Holshire, Soviet research from the 1950s showing antiparasitics had anti-tumor effects was classified by the CIA and only declassified in 2011. Ivermectin won the Nobel Prize in Medicine in 2015 for its effectiveness against parasitic diseases.
Holshire said that parasites may be a root cause of some cancers through mechanisms involving tissue damage and cellular disruption. The treatment showed mild side effects in 25 percent of patients, primarily gastrointestinal issues, and can be used alongside conventional cancer therapies.
The findings indicate that repurposed antiparasitic drugs could provide a low-cost alternative to expensive chemotherapy regimens, potentially transforming cancer treatment accessibility worldwide.
